Cell News and Research

RSS

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

NIH approves BioTime's two human embryonic stem cell lines for clinical use

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that two human embryonic stem (hES) cell lines, ESI-014 and ESI-017, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry.

4 Jun 2011

Cancer vaccine shows improved response rate in patients

A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.

3 Jun 2011

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies.

3 Jun 2011

Mimicry allows bacteria to evade host's defense responses

Deadly bacteria may be evolving antibiotic resistance by mimicking human proteins, according to a new study by the Translational Genomics Research Institute (TGen).

3 Jun 2011

Preclinical study: Combination therapy of SPX-106 and D-tagatose reduces triglycerides and cholesterol

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.

3 Jun 2011

Medical researchers uncover a novel approach to treat Huntington's disease

Medical researchers may have uncovered a novel approach to treat an incurable and ultimately fatal neurodegenerative disease that affects hundreds of thousands of people.

3 Jun 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

3 Jun 2011

New report: Life science tools market to reach over $80B by 2016

The life science tools market will reach over $80 billion by 2016, according to a new report on companiesandmarkets.com. The life science tools market has shown steady growth over the last couple of years despite the economic downturn.

3 Jun 2011

Stevens Institute of Technology to host conference on bacteria-material interactions

On June 9-10, Stevens Institute of Technology will host the Stevens Conference on Bacteria-Material Interactions, an event that covers the latest multi-disciplinary research in the area of infection-resistant biomaterials.

3 Jun 2011

New slow-release compound protects against Huntington's and Alzheimer's

A study in a special early online publication of Cell, a Cell Press publication, reveals a promising new slow-release compound that protects mice against the neurodegenerative effects of both Huntington's and Alzheimer's disease.

3 Jun 2011

Patch-clamp recording reveals subtle differences between two neurotransmitter-gated ion channels

Using a high-resolution single-molecule study technique, University of Illinois researchers have seen the very subtle differences between two branches of an important family of neurotransmitter-gated ion channels.

3 Jun 2011

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. today announced that they have entered into a agreement to provide IMUC with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

3 Jun 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011

Scientists identify protein sorting mechanism used by salivary gland

University of Louisville researchers are one step closer to helping millions of people whose salivary glands no longer work because of disease or damage from treatment of diseases.

3 Jun 2011

Scientists uncover new therapeutic target that could prevent stress-related cell death

Scientists from the Florida campus of The Scripps Research Institute have uncovered a potentially important new therapeutic target that could prevent stress-related cell death, a characteristic of neurodegenerative diseases such as Parkinson's, as well as heart attack and stroke.

3 Jun 2011

Scientists discover new compound that inhibits bitterness

Although bitterness can sometimes be desirable - such as in the taste of coffee or chocolate - more often bitter taste causes rejection that can interfere with food selection, nutrition and therapeutic compliance. This is especially true for children. Now, scientists from the Monell Center and Integral Molecular describe the discovery of a compound that inhibits bitterness by acting directly on a subset of bitter taste receptors.

3 Jun 2011

'Provision of choice' strategy helps improve vegetable consumption in children

A gesture as simple as allowing children to freely choose the vegetables they want to eat helps to increase the consumption of these foods in children, as University of Granada has found.

3 Jun 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

3 Jun 2011

VisiInc and MMRGlobal announce agreement to launch MyMedicalRecords in Australia

MMRGlobal, Inc. and VisiInc PLC (VZJ) have entered into an agreement to launch MMRGlobal’s patented consumer and professional health IT products and services, including MMRPro for healthcare professionals (www.mmrprovideos.com) and the MyMedicalRecords Personal Health Record (PHR) (www.mmrvideos.com), on the Visi™ platform utilizing the Vistime product. Initially, the two companies will collaborate on offering products and services jointly to the health technology market in Australia, which is currently projected to be as much as $2.4 billion this year.

2 Jun 2011